Back to News
Market Impact: 0.45
Longeveron's Laromestrocel Misses Primary Endpoint In Phase 2b HLHS Trial; Stock Down 59%
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Longeveron's Phase 2b ELPIS II trial of laromestrocel in infants with hypoplastic left heart syndrome failed its primary endpoint. The therapy did not demonstrate improvement in right ventricular ejection fraction at 12 months, representing a significant clinical-development setback likely to pressure LGVN shares.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.65
Ticker Sentiment
LGVN-0.90
More News
- Binance seeks to shore up confidence after record $6.3 billion heist
- Why is Alstom stock down 27% today?
- Alstom shares sink 28% after outlook cut on Coradia Max execution issues
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- Binance sees outflows stabilising as exchange returns online after $6.3 billion heist
- Apollo launches $11 billion private credit platform, backed by Abu Dhabi